An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV

BMC Infectious Diseases

Ze Chen¹  Zhenyuan Xie⁴  Fang Fang⁵  Jianjun Chen²  Hongbo Zhang²  Quanjiao Chen²  Xingxing Fu¹  Chaoyang Huang⁵  Yanfeng Yao²  Huadong Wang³ 

[1] Shanghai Institute of Biological Products, Shanghai 200052, China;State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Hubei, China;Graduate University of Chinese Academy of Sciences, Beijing 100049, China;Xie Tu Community Medical Service Center, Xuhui, District of Shanghai, China;College of Life Science, Hunan Normal University, Changsha 410081, Hunan, China

关键词: Long-term protective immunity;    Adjuvant;    Inactivated vaccine;    Cytomegalovirus;   

Others  :  1134130
DOI  :  10.1186/1471-2334-14-195

 received in 2013-09-09, accepted in 2014-04-04,  发布年份 2014

【 摘 要 】

Background

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that causes serious problems in immunocompromised or immunologically immature hosts. Vaccination is the preferred approach for prevention of HCMV infection, but so far no approved HCMV vaccine is available. In this study, we assessed the immunogenicity and protective immunity of a formalin-inactivated murine cytomegalovirus vaccine (FI-MCMV) in a mouse model in combination with adjuvants MF59, alum, or chitosan.

Methods

Specific-pathogen-free BALB/c mice aged 6–8 weeks were immunized twice, 3 weeks apart, with various doses of FI-MCMV (0.25 μg, 1 μg, 4 μg) with or without adjuvant. Mice were challenged with a lethal dose (5 × LD₅₀) of a more virulent mouse salivary gland-passaged MCMV 3 weeks after the second immunization. The protective immunity of the vaccine was evaluated by determining the survival rates, residual spleen and salivary gland viral loads, body weight changes, and serum anti-MCMV IgG titers.

Results

Immunization with FI-MCMV vaccine induced a high level of specific antibody response. Antigen sparing was achieved by the addition of an adjuvant, which significantly enhanced the humoral response to vaccine antigens with a wide range of doses. The level of live virus detected in the spleen on day 5 and in the salivary glands on day 21 after the lethal challenge was significantly lower in adjuvant-treated groups than in controls. Survival rates in adjuvant-treated groups also increased significantly. Furthermore, these protective immune responses were sustained for at least 6 months following immunization.

Conclusions

These results show that inactivated MCMV vaccine is effective, and that the adjuvanted FI-MCMV vaccine provides more effective and longer-term protection than the adjuvant-free vaccine.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hassan J, Connell J: Translational mini-review series on infectious disease: Congenital cytomegalovirus infection: 50 years on. Clin Exp Immunol 2007, 149(2):205-210.
• [2]Morello CS, Kelley LA, Munks MW, Hill AB, Spector DH: DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol 2007, 81(14):7766-7775.
• [3]Morello CS, Ye M, Spector DH: Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol 2002, 76(10):4822-4835.
• [4]Zhong J, Khanna R: Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 2007, 5(3):449-459.
• [5]Demmler GJ: Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis 1996, 11:135-162.
• [6]Lazzarotto T, Lanari M: Why is cytomegalovirus the most frequent cause of congenital infection? Expert Rev Anti Infect Ther 2011, 9(10):841-843.
• [7]Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R: Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39(2):233-239.
• [8]Shen S, Wang S, Britt WJ, Lu S: DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 2007, 25(17):3319-3327.
• [9]Griffiths PD: The 2001 Garrod Lecture - The treatment of cytomegalovirus infection. J Antimicrob Chemother 2002, 49(2):243-253.
• [10]Sung H, Schleiss MR: Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010, 9(11):1303-1314.
• [11]Pass RF, Zhang CP, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G: Vaccine Prevention of Maternal Cytomegalovirus Infection. N Engl J Med 2009, 360(12):1191-1199.
• [12]Brune W, Hengel H, Koszinowski UH: A mouse model for cytomegalovirus infection. Curr Protoc Immunol 2001, Chapter 19:Unit 19 17.
• [13]Qureshi MH, Garvy BA, Pomeroy C, Inayat MS, Oakley OR: A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: effects of virus-induced immunomodulation on disease progression. Virus Res 2005, 114(1–2):35-44.
• [14]Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
• [15]Brunner R, Jensen-Jarolim E, Pali-Scholl I: The ABC of clinical and experimental adjuvants-A brief overview. Immunol Lett 2010, 128(1):29-35.
• [16]Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377(9773):1256-1263.
• [17]Tritto E, Mosca F, De Gregorio E: Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25–26):3331-3334.
• [18]Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW: Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25(11):2085-2094.
• [19]Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A: Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 2011, 10(7):1053-1061.
• [20]Morello CS, Ye M, Hung S, Kelley LA, Spector DH: Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 2005, 79(1):159-175.
• [21]Tolpin MD, Starr SE, Arbeter AM, Plotkin SA: Inactivated mouse cytomegalovirus vaccine: preparation, immunogenicity, and protective effect. J Infect Dis 1980, 142(4):569-574.
• [22]Geoffroy F, Moachon N, Rodwell J, Quash GA: Murine cytomegalovirus inactivated by sodium periodate is innocuous and immunogenic in mice and protects them against death and infection. Vaccine 1996, 14(17–18):1686-1694.
• [23]Tebourbi L, Courtot AM, Duchateau R, Loeuillet A, Testart J, Cerutti I: Experimental inoculation of male mice with murine cytomegalovirus and effect on offspring. Hum Reprod 2001, 16(10):2041-2049.
• [24]Boeckh M, Geballe AP: Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011, 121(5):1673-1680.
• [25]Cicin-Sain L, Bubic I, Schnee M, Ruzsics Z, Mohr C, Jonjic S, Koszinowski UH: Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol 2007, 81(24):13825-13834.
• [26]Plotkin SA: Is there a formula for an effective CMV vaccine? J Clin Virol 2002, 25:S13-S21.
• [27]Schleiss MR, Heineman TC: Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005, 4(3):381-406.
• [28]Rey-Ladino J, Ross AG, Cripps AW, McManus DP, Quinn R: Natural products and the search for novel vaccine adjuvants. Vaccine 2011, 29(38):6464-6471.
• [29]Cataldo DM, Van Nest G: The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997, 15(16):1710-1715.
• [30]Ninomiya A, Imai M, Tashiro M, Odagiri T: Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25(18):3554-3560.
• [31]O'Hagan DT, Wack A, Podda A: MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development? Clin Pharmacol Ther 2007, 82(6):740-744.
• [32]Kenney RT, Edelman R: Survey of human-use adjuvants. Expert Rev Vaccines 2003, 2(2):167-188.
• [33]Marrack P, McKee AS, Munks MW: Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
• [34]Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N: Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharm J 2011, 19(4):197-206.
• [35]Coffman RL, Sher A, Seder RA: Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
• [36]Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A: Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29(9):1812-1823.
• [37]Chang H, Li X, Teng Y, Liang Y, Peng B, Fang F, Chen Z: Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. DNA Cell Biol 2010, 29(9):563-568.
• [38]Khanna R, Diamond DJ: Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 2006, 12(1):26-33.